An assessment of the screening method to evaluate vaccine effectiveness: The case of 7-valent pneumococcal conjugate vaccine in the United States

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Cohen, Adam L ^a   Taylor, Thomas ^a   Farley, Monica M ^b   Schaffner, William ^c   Lesher, Lindsey J ^d   Gershman, Kenneth A ^e   Bennett, Nancy M ^f   Reingold, Arthur ^g   Thomas, Ann ^h   Baumbach, Joan ⁱ   Harrison, Lee H ^j   Petit, Susan ^k   Beall, Bernard ^a   Zell, Elizabeth ^a   Moore, Matthew ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MINNESOTA DEPARTMENT OF HEALTH   (United States)

^e Colorado Department of Health and the Environment ^*  (United States)

^f UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Oregon Department of Health   (United States)

ⁱ NEW MEXICO DEPARTMENT OF HEALTH   (United States)

^j JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^k CDC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; TREND STUDY; UNITED STATES;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS PNEUMONIAE;

EID: 84864758091     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041785     Document Type: Article

References (20)

1. World Health Organization (2007) Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Wkly Epidemiol Rec 82: 93-104.
2. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreno RA, et al. (2009) Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. pp. CD004977.
3. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, et al. (2006) Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 368: 1495-1502.
4. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, et al. (1985) Field evaluation of vaccine efficacy. Bull World Health Organ 63: 1055-1068.
5. Farrington CP, (1993) Estimation of vaccine effectiveness using the screening method. Int J Epidemiol 22: 742-746.
6. Kupper L, McMichael A, Spirtas R, (1975) A hybrid epidemiologic study design useful in estimating relative risk. JASA 70: 524-528.
7. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP, (2003) Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 188: 481-485.
8. Guris D, Strebel PM, Tachdjian R, Bardenheier B, Wharton M, et al. (1997) Effectiveness of the pertussis vaccination program as determined by use of the screening method: United States, 1992-1994. J Infect Dis 176: 456-463.
9. McMorrow ML, Gebremedhin G, van den Heever J, Kezaala R, Harris BN, et al. (2009) Measles outbreak in South Africa, 2003-2005. S Afr Med J 99: 314-319.
10. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME, (2004) Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364: 365-367.
11. Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, et al. (2007) Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England. Emerg Infect Dis 13: 12-17.
12. Seyler T, Bella A, Puzelli S, Donatelli I, Rizzo C, (2012) Estimating pandemic vaccine effectiveness in two Italian regions using the screening method, 2009-2010. Vaccine 30(2): 109-111.
13. Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, et al. (2001) Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis 7: 92-99.
14. Smith PJ, Nuorti JP, Singleton JA, Zhao Z, Wolter KM, (2007) Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey. Pediatrics 120: e1165-1173.
15. Centers for Disease Control and Prevention (2011) National and state vaccination coverage among children aged 19-35 months-United States, 2010. MMWR Morb Mortal Wkly Rep 60: 1157-1163.
16. Carvalho Mda G, Pimenta FC, Gertz RE, Joshi HH, Trujillo AA, et al. (2009) PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J Clin Microbiol 47: 554-559.
17. United States Census Bureau Population estimates. Available: https://www.census.gov/popest/datasets.html. Accessed 2009 Mar 10.
18. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, et al. (2010) Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201: 32-41.
19. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
20. De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, et al. (2012) Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine 30: 4067-4072.